72
Views
0
CrossRef citations to date
0
Altmetric
Research Article

Prolyl endopeptidase activity in bronchoalveolar lavage fluid: a novel diagnostic biomarker in a guinea pig model of invasive pulmonary aspergillosis

, , , , , , , & show all
Pages 592-602 | Received 14 Jun 2012, Accepted 18 Dec 2012, Published online: 28 Jan 2013
 

Abstract

Improved diagnostics are needed to detect invasive pulmonary aspergillosis, a life-threatening infection caused by the pathogenic fungus Aspergillus fumigatus. We are investigating secreted fungal proteases as novel biomarkers for the diagnosis of this disease. Although the A. fumigatus genome encodes a multitude of secreted proteases, few have been experimentally characterized. Here, we employed an unbiased combinatorial library of internally quenched fluorogenic probes to detect infection-associated proteolysis in the lungs of guinea pigs experimentally infected with A. fumigatus. Comparative protease activity profiling revealed a prolyl endopeptidase activity that is reproducibly induced during infection but is not observed in healthy animals. This proteolytic activity was found in four independent animal experiments involving two A. fumigatus isolates. We synthesized a small, focused fluorogenic probe library to define the substrate specificity of the prolyl endopeptidase substrate motif and to identify optimal Probe sequences. These efforts resulted in the identification of a panel of six individual substrate-based fluorescent probes capable of detecting infection in guinea pigs with high statistical significance (P<0.005 in most cases). Receiver operating characteristic analyses demonstrated that this fluorogenic assay could detect A. fumigatus infection-associated proteolysis with comparable sensitivity and specificity as existing diagnostic procedures, suggesting that further optimization of the methodology may lead to improved diagnostics options for invasive pulmonary aspergillosis.

Acknowledgments

The authors wish to acknowledge the encouragement and guidance of Dr Joe Perrone, Director of Diagnostics at SRI Biosciences, and Dr Walter Moos, Vice President of SRI Biosciences. This work was supported by grant R21AI08502 and contract N01AI30041 and HHSN2722010000381 from the National Institute of Allergy and Infectious Diseases (NIAID). SRI International's Center for Advanced Drug Research was established through funding support from the Commonwealth of Virginia.

Declaration of interest: The authors report no conflicts of interest. The authors alone are responsible for the content and the writing of the paper.

Log in via your institution

Log in to Taylor & Francis Online

There are no offers available at the current time.

Related Research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.